Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Dermatologic 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

venetoclax 190Cyclophosphamide 123Azacitidine 112Cytarabine 108fludarabine 91Specimen Handling 74Biopsy 53Daunorubicin 42Methotrexate 41Dexamethasone 38Rituximab 34blinatumomab 32Vincristine 32Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Whole-Body Irradiation 26Magnetic Resonance Spectroscopy 26obinutuzumab 25Idarubicin 25acalabrutinib 23Prednisone 23Mycophenolic Acid 23Melphalan 21Busulfan 21gilteritinib 19Mercaptopurine 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × EPOCH protocol × Other hematologic neoplasm × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡